Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to characterize the safety, and efficacy of
Dexmedetomidine (DEX) administered as an intravenous (IV) loading dose followed by a
continuous IV infusion in preterm subjects, ages ≥ 28 weeks through < 36 weeks gestational
age.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer